Developing a treatment to prevent hearing loss from Cisplatin chemotherapy.
Official title: Development of UPR-Targeted Treatment for Cisplatin-Induced Ototoxicity.
Funded at Jacaranda Biosciences, INC. · NIH-11004730 · Data updated 2026-11-12
This study is looking at new ways to protect your hearing from damage caused by a common chemotherapy drug called Cisplatin, which might be especially helpful for patients who are worried about losing their hearing during treatment.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Jacaranda Biosciences, INC. NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project start | July 2, 2024 |
| Project end | June 30, 2025 |
| Funding year | 2024 |
| Award (this year) | $304,762 |
| NIH project number | 1R43DC021398-01A1 |
| Project ID | NIH-11004730 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients who are receiving Cisplatin treatment and are at risk of developing hearing loss.
✕Less likely to help
Patients who are not undergoing Cisplatin treatment or do not have a risk of hearing loss may not benefit from this research.
What this research studies
This research focuses on creating new compounds that can protect against hearing loss caused by Cisplatin, a common chemotherapy drug. The approach involves targeting the unfolded protein response (UPR) in the cochlea, which is crucial for preventing cell death and preserving hearing. By testing and optimizing these compounds in animal models, the researchers aim to establish a foundation for future human trials. Patients who experience hearing loss due to Cisplatin treatment may find this research particularly relevant.
Why it matters
Potential benefit: If successful, this research could significantly reduce the incidence of hearing loss in patients undergoing Cisplatin chemotherapy.
How similar studies have gone: Previous research has shown promise in using UPR modulation to prevent hearing loss in animal models, indicating a potential for success in this novel approach.
Where this research is happening
-
Jacaranda Biosciences, INC.
San Francisco, United States Active
Researchers
- Principal investigator: Chouchane, Malek — Jacaranda Biosciences, INC.
- Study coordinator: Chouchane, Malek
Related research
Other NIH-funded projects on the same topics.
-
eiF2B Activators for Noise-Induced Hearing Loss
A new small-molecule treatment approach aims to help people with hearing loss caused by loud noises.
-
New treatment for hearing loss caused by loud noise
This study is testing a new treatment for people with noise-induced hearing loss, especially those who have been around loud sounds, by using a special medicine that targets a specific process in our cells to help improve their hearing.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.